Panel Upholds Board, Continues To Disagree On Impact Of Arthrex
WASHINGTON, D.C. — A panel majority of the Federal Circuit U.S. Court of Appeals on Nov. 19 affirmed that two patents relating to manmade insulin are obvious, but a dissenting judge...To view the full article, register now.
Already a subscriber? Click here to view full article